Medicure Company Description

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States.

The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction.

It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological indications, such as Tardive Dyskinesia.

It offers products through retail and mail order pharmacies. The company was founded in 1997 and is headquartered in Winnipeg, Canada.

Medicure Inc.

Country	Canada
Founded	1997
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	38
CEO	Albert Friesen

Contact Details

Address: 2-1250 Waverley Street Winnipeg, R3T 6C6 Canada
Phone	204 487 7412
Website	medicure.com

Stock Details

Ticker Symbol	MPH
Exchange	TSX Venture Exchange
Fiscal Year	January - December
Reporting Currency	CAD
ISIN Number	CA58469E4085
SIC Code	2836

Key Executives

Name	Position
Dr. Albert David Friesen Ph.D.	Founder, Chief Executive Officer and Chairman of the Board
Dr. Neil Owens Ph.D.	President and Chief Operating Officer
Haaris Uddin B.Com., CPA	Chief Financial Officer
Dr. Reuben Saba Ph.D.	Vice President of Scientific and Medical Affairs